

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM868893

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BRIDGEBIO PHARMA, INC.		01/17/2024	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Blue Owl Capital Corporation, as Administrative Agent		
Street Address:	399 Park Avenue, 37th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10022		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	6413178	BRIDGEBIO	
Registration Number:	6480657	BRIDGEBIO	
Registration Number:	7018947	BRIDGEBIO	
Serial Number:	97714245	BRIDGEBIO	
CORRESPONDENCE DATA			
Fax Number:	4156932222		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4156932000		
Email:	crhem@cooley.com		
Correspondent Name:	Cooley LLP		
Address Line 1:	3 Embarcadero Center, 20th Floor		
Address Line 4:	San Francisco, CALIFORNIA 94111		
ATTORNEY DOCKET NUMBER:	347580-104		
NAME OF SUBMITTER:	C. Rhem		
SIGNATURE:	/CR/		
DATE SIGNED:	01/17/2024		
Total Attachments: 5			
source=Blue Owl - BBIO - Trademark Security Agreement - 01.17.2024#page1.tif			

CH \$115.00 6413178

source=Blue Owl - BBIO - Trademark Security Agreement - 01.17.2024#page2.tif

source=Blue Owl - BBIO - Trademark Security Agreement - 01.17.2024#page3.tif

source=Blue Owl - BBIO - Trademark Security Agreement - 01.17.2024#page4.tif

source=Blue Owl - BBIO - Trademark Security Agreement - 01.17.2024#page5.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of January 17, 2024 (this “**Agreement**”), is entered into by and among BridgeBio Pharma, Inc., a Delaware corporation (the “**Grantor**”), and Blue Owl Capital Corporation (the “**Assignee**”), as Administrative Agent, pursuant to (i) that certain Pledge and Security Agreement, dated as of January 17, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), among the Assignee, the Grantor and the other grantors party thereto, and (ii) that certain Financing Agreement, dated as of January 17, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Financing Agreement**”), among the Grantor, certain of the Grantor’s affiliates, the Assignee and certain Lenders party thereto.

Capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or, if not defined therein, the Financing Agreement.

WHEREAS, pursuant to the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the federally registered Trademarks set forth on Schedule A hereto as of the date hereof, and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor and the Assignee hereby agree as follows:

(a) Grant of Security Interest

(i) Subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in and continuing Lien on all of the Grantor’s right, title and interest in, to and under the Trademarks, whether now owned or existing hereafter acquired or arising and wherever located, as collateral security for the prompt and complete payment and performance in full when due (whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise) of the Secured Obligations. For the purposes of this Agreement, “**Trademarks**” means all United States trademarks and foreign trademarks, trade names, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, all registrations and applications for any of the foregoing including, but not limited to: (i) the registrations and applications referred to in Schedule A hereto, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by the foregoing, (iv) all rights corresponding thereto throughout the world, (v) the right to sue for past, present and future infringement or dilution of any of the foregoing or for any injury to goodwill, and (vi) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit; provided that no Excluded Assets shall be included in the Trademarks.

(ii) Schedule A hereto contains a true and accurate list of all of the Grantor’s registrations and applications for registration for the Trademarks in the United States (excluding Internet domain names) existing as of the date hereof.

(iii) The security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee under the Security Agreement. In the event that any of the

provisions of this Agreement are in conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

(b) Modifications

This Agreement or any provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement without obtaining the Grantor's signature to such modification, to the extent that such modification constitutes an amendment of Schedule A hereto, to add any right, title or interest in any Trademarks owned or subsequently acquired by the Grantor or to delete any reference to any right, title or interest in any Trademarks in which the Grantor no longer has or claims any right, title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any Trademark to the security interests and perfection created or contemplated hereby or by the Security Agreement.

(c) Applicable Law

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

(d) Counterparts; Electronic Signatures

This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement. For the purposes of this Section 4, "electronic signature" shall be construed so as to include the electronic signature of each witness, if any, of an electronic signature used to execute this Agreement. The words "execution", "execute", "signed", "signature" and words of like import in this Agreement or in related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

(e) CONSENT TO JURISDICTION; WAIVER OF JURY TRIAL

SECTIONS 10.15 (CONSENT TO JURISDICTION) and 10.16 (WAIVER OF JURY TRIAL) OF THE FINANCING AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE, *MUTATIS MUTANDIS*.

[Signature Page Follows]

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

ASSIGNEE:

BLUE OWL CAPITAL CORPORATION

BY: BLUE OWL CREDIT ADVISORS LLC,
its Investment Advisor

By: 
Name: Meenal Mehta
Title: Authorized Signatory

Address of Assignee:

Blue Owl Capital Corporation
399 Park Avenue, 37th Floor
New York, NY 10022
Email: finance@blueowl.com;
adminagent@blueowl.com

with a copy (which shall not constitute notice) to:

Cooley LLP
1299 Pennsylvania Avenue, NW, Suite 700
Washington, DC 20004-2400
Attention: Michael Tollini
Email: mtollini@cooley.com

GRANTOR:


BRIDGEBIO PHARMA, INC.

By:
Name: Neil Kumar
Title: President


Address of Grantor:
BridgeBio Pharma, Inc.
3160 Porter Drive, Suite 250,
Palo Alto, CA 94304
Attention: Chief Legal Officer
Email: Legal@Bridgebio.com

Schedule A to TRADEMARK SECURITY AGREEMENT

U.S. Registered Trademarks

Grantor	Trademark Name	Application Number	Filing Date	Status	Registration Number	Registration Date
BridgeBio Pharma, Inc.	BRIDGEBIO	90256769	10/15/2020	Registered	6413178	7/6/2021
BridgeBio Pharma, Inc.		90256777	10/15/2020	Registered	6480657	9/7/2021
BridgeBio Pharma, Inc.	BRIDGEBIO	97470841	6/22/2022	Registered	7018947	4/4/2023

U.S. Applications of Registration of Trademarks

Grantor	Trademark Name	Application Number	Filing Date	Status	Registration Number	Registration Date
BridgeBio Pharma, Inc.		97714245	12/12/2022	Pending	N/A	N/A